Previous 10 | Next 10 |
Image source: The Motley Fool. Neuronetics, Inc. (NASDAQ: STIM) Q4 2020 Earnings Call Mar 02, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Neuronetics, Inc. (STIM) Q4 2020 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q4 2020 Results Conference Call March 02, 2021 08:30 AM ET Company Participants Mark Klausner - Westwicke Partners, LLC Keith Sullivan - President & Chief Executive Officer Stephen Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor - Wi...
Neuronetics (STIM): Q4 GAAP EPS of -$0.19 beats by $0.08.Revenue of $15.58M (-10.3% Y/Y) beats by $1.39M.Press Release For further details see: Neuronetics EPS beats by $0.08, beats on revenue
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its f...
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that c...
MALVERN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced t...
MALVERN, Pa., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced three execut...
MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced t...
MALVERN, Pa., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric dis...
Neuronetics (STIM) has priced its public offering of 4.84M common shares at $15.50/share, for expected gross proceeds of ~$75M.Underwriters' over-allotment is an additional 726K shares. Net proceeds will be used for general corporate purposes, including working capital and R&D activities....
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is committed to supporting adolescents ...
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing,...
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first qu...